Company news

Harmony Biosciences Holdings, Inc. news in 2023

Harmony Biosciences Holdings, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Harmony Biosciences announces positive topline data from Phase 2 signal detection study evaluating pitolisant in adult patients with myotonic dystrophy type 1

December 6, 2023

Harmony Biosciences to present results from behavioral study in 22Q11.2 deletion syndrome at american college of neuropsychopharmacology annual meeting

December 4, 2023

Harmony Biosciences to participate in piper sandler 35th annual healthcare conference

November 15, 2023

Harmony Biosciences ranked among top 25 fastest-growing companies in North America on the 2023 Deloitte Technology Fast 500™

November 14, 2023

Harmony Biosciences appoints Peter Anastasiou to its board of directors

November 7, 2023

Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results

October 30, 2023

Harmony Biosciences showcases the newest Patients at the Heart and Progress at the Heart award recipients

October 25, 2023

Harmony Biosciences to report third quarter 2023 financial results on October 31, 2023

October 16, 2023

Harmony Biosciences announces topline data from phase 3 INTUNE study evaluating pitolisant in patients with idiopathic hypersomnia

October 12, 2023

Harmony Biosciences completes acquisition of zynerba pharmaceuticals and expands pipeline

October 10, 2023

Harmony Biosciences presents new secondary outcome data from Phase 2 signal detection study in patients with Prader-Willi syndrome

October 4, 2023

Harmony Biosciences announces extension of tender offer to acquire zynerba pharmaceuticals, Inc.

September 26, 2023

Harmony Biosciences president & CEO Jeffrey M. Dayno, m.d., named to 2023 PharmaVoice 100 list of top industry leaders

September 19, 2023

Harmony Biosciences to participate in 2023 cantor global healthcare conference

September 12, 2023

Harmony Biosciences announces US food & Drug Administration Orphan Drug designation for pitolisant for treatment of idiopathic hypersomnia

September 6, 2023

Harmony Biosciences reiterates confidence in WAKIX® (pitolisant) patents following favorable decision by U.S. patent and Trademark Office (USPTO) to deny petition for reexamination

August 27, 2023

Harmony Biosciences to acquire zynerba pharmaceuticals, Inc.

August 13, 2023

Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates

July 31, 2023

Harmony Biosciences announces $125 million share repurchase program

July 31, 2023

Harmony Biosciences enters into $185 million term loan facility

July 26, 2023

Harmony Biosciences Announces Funding for Unique Community Initiatives Through its Patients and Progress at the Heart Awards Programs

July 24, 2023

Harmony Biosciences announces plans to initiate Phase 3 registrational study of pitolisant in Prader-Willi syndrome following positive End-of-Phase 2 meeting with the U.S. food and drug administration

July 19, 2023

Harmony Biosciences to report second quarter 2023 financial results on August 1, 2023

July 17, 2023

Harmony Biosciences announces positive Phase 2 signal detection study evaluating pitolisant for excessive daytime sleepiness in Prader-Willi syndrome at sleep 2023

June 5, 2023

Harmony Biosciences to participate in goldman sachs 44th annual global healthcare conference

May 29, 2023

Harmony Biosciences completes enrollment of Phase 3 registrational INTUNE study in idiopathic hypersomnia

May 24, 2023

Harmony Biosciences to present new WAKIX® (pitolisant) safety and efficacy data at SLEEP 2023 annual meeting

May 9, 2023

Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates

May 1, 2023

Harmony Biosciences announces Jeffrey M. Dayno, m.d. appointed President & Chief Executive Officer

April 23, 2023

Harmony Biosciences to report first quarter 2023 financial results on May 2, 2023

April 19, 2023

Harmony Biosciences announces accelerated timeline for Phase 3 INTUNE study in idiopathic hypersomnia

March 28, 2023

Harmony Biosciences continues community commitment in 2023 with Patients at the Heart and Progress at the Heart nonprofit funding programs

February 27, 2023

Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

February 20, 2023

Harmony Biosciences certified as a Great Place to Work® for fifth consecutive year

February 16, 2023

Harmony Biosciences to report fourth quarter and full year 2022 financial results on February 21, 2023

February 6, 2023

Harmony Biosciences appoints Jeffrey M. Dayno, md as interim CEO and expands role of jeff aronin to Executive Chairman

January 5, 2023

Calls in 2023

Decks in 2023